Simvastatin
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Simvastatin: From Hypercholesterolemia to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is a well-established HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol. The TxGNN model predicts it may be effective for Familial Hypercholesterolemia (FH), with 19 clinical trials and 18 publications currently supporting this direction. Notably, the underlying evidence itself indicates this is largely an already-established, guideline-recognized use of statins rather than a truly novel indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally captured in this jurisdiction’s regulatory data (drug currently not marketed here); globally, simvastatin is an HMG-CoA reductase inhibitor approved for hypercholesterolemia/dyslipidemia |
| Predicted New Indication | Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, structured mechanism-of-action data is not available in this evidence pack (flagged as a data gap). Based on the mechanistic rationale captured alongside the prediction, simvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptor expression — the core pharmacological basis for treating familial hypercholesterolemia (FH).
FH is a genetic disorder of LDL receptor function (or related pathways) that causes markedly elevated LDL-C from birth. Because statins act directly on the LDL-receptor pathway, they are already the pharmacological backbone of FH management in current clinical guidelines — this is not really a “new” indication being uncovered, but rather a core, textbook use of the statin drug class.
The evidence pack’s own rationale is explicit about this: “此為 statin 藥理學核心適應症而非真正新用途” — i.e., this is a core statin indication rather than a genuine repurposing signal. The high TxGNN score therefore likely reflects the model correctly recovering a strong, well-known drug–disease relationship in the knowledge graph, rather than identifying a novel off-label opportunity. This distinction matters for how the “new indication” label should be interpreted downstream.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: direct comparison of ezetimibe + high-dose simvastatin vs. simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT02107898 | Phase 3 | Completed | 216 | RCT of alirocumab added on top of stable statin therapy in heFH/high-CV-risk patients not controlled by lipid-modifying therapy |
| NCT01623115 | Phase 3 | Completed | 486 | Placebo-controlled RCT of alirocumab in heFH patients inadequately controlled on background lipid-modifying therapy (incl. statins) |
| NCT03510884 | Phase 3 | Completed | 153 | RCT of alirocumab vs. placebo in children/adolescents with heFH on stable statin background therapy |
| NCT03510715 | Phase 3 | Completed | 18 | Open-label study of alirocumab in children/adolescents with homozygous FH on background treatment |
| NCT03884452 | Phase 3 | Completed | 50 | Efficacy/safety of ezetimibe added to atorvastatin or simvastatin in homozygous FH |
| NCT00129402 | Phase 3 | Completed | 248 | RCT of ezetimibe + simvastatin vs. simvastatin alone in adolescents (10–17 y) with heFH |
| NCT01070966 | N/A | Completed | 2089 | Post-marketing re-examination survey of VYTORIN (ezetimibe/simvastatin) safety and efficacy in routine practice |
| NCT00654446 | Phase 3 | Completed | 442 | Open-label comparison of renal effects of rosuvastatin vs. simvastatin in Fredrickson Type IIa/IIb dyslipidemia, including heFH |
| NCT01507831 | Phase 3 | Completed | 2341 | Long-term safety/tolerability RCT of alirocumab in high-CV-risk hypercholesterolemia patients on background lipid-modifying therapy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31696945 | 2019 | Review (Cochrane, Tier 1) | Cochrane Database Syst Rev | Systematic review of statins (including simvastatin) for children with FH |
| 41824552 | 2026 | Guideline (Tier 1) | Circulation | 2026 ACC/AHA dyslipidemia management guideline, replacing the 2018 cholesterol guideline |
| 18376000 | 2008 | RCT | New England Journal of Medicine | ENHANCE trial: simvastatin with or without ezetimibe in FH, assessing atherosclerosis progression |
| 27417002 | 2016 | Outcomes Study | Journal of the American College of Cardiology | Statin treatment reduces coronary artery disease events and mortality in heterozygous FH |
| 15794711 | 2005 | Review (Tier 2) | Expert Opinion on Drug Safety | Benefits and long-term safety/tolerability assessment of simvastatin in FH |
| 35629051 | 2022 | Cohort (Tier 2) | Journal of Clinical Medicine | Simvastatin treatment and cellular immunity parameters in children with FH |
| 12908847 | 2003 | Review | Drug Safety | Benefits and risks of simvastatin specifically in FH patients |
| 21173733 | 2010 | Cohort | International Angiology | Long-term efficacy/safety of ezetimibe/simvastatin combination in FH |
| 11383320 | 2001 | Comparative Study | Nutrition, Metabolism and Cardiovascular Diseases | Atorvastatin vs. simvastatin for LDL-C goal attainment in heterozygous FH |
| 1346327 | 1992 | Observational | Lancet | Early report on simvastatin’s effect on lipoprotein(a) |
US Market Information
Simvastatin is currently not marketed in this jurisdiction — no NDA/license records are on file (total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information. Structured warnings, contraindications, and drug–drug interaction data for this jurisdiction are currently unavailable and have not yet been retrieved.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Three completed Phase 3 RCTs, a Cochrane systematic review, and inclusion in the 2026 ACC/AHA dyslipidemia guideline (L1-level evidence) support statin therapy — including simvastatin — as standard-of-care for FH. However, this is best understood as confirming an already-established core use of the statin class rather than a novel repurposing opportunity, and the drug is not currently marketed in this jurisdiction, with the local safety label (warnings/contraindications) still an unresolved blocking data gap.
To proceed, the following is needed:
- Obtain the TFDA-equivalent package insert (warnings, contraindications) — currently a blocking gap for any safety review
- Obtain structured mechanism-of-action data via DrugBank API (currently a data gap)
- Confirm local regulatory/import pathway status, since the drug is presently unmarketed here
- Clarify internally that this “prediction” reflects an established clinical use rather than a genuine off-label repurposing signal, to avoid overstating novelty in downstream communications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.